For the Inventor, By the Inventor

Enter assignee name

Weston, MA, United States of America

Biogen Idec, Inc.

USPTO Granted Patents = 46

CIPO Patents = 5

EPO Patents = 9

Trademarks = 2

Forward Citations = 1,009

Loading Chart...

Loading Chart...

62 inventors (with patents filed for the assignee):

Nabil Hanna (23 out of 40 patents)

Darrell R Anderson (14 out of 22 patents)

Peter Brams (12 out of 24 patents)

4. Mitchell E Reff (7 out of 25 patents)

5. Roland A Newman (7 out of 30 patents)

6. Antonio J Grillo-Lopez (6 out of 9 patents)

7. Christine A White (5 out of 9 patents)

8. John G Curd (5 out of 8 patents)

9. William H Rastetter (4 out of 18 patents)

10. Kandasamy Hariharan (3 out of 11 patents)

11. Paul Chinn (3 out of 7 patents)

12. Gary R Braslawsky (3 out of 4 patents)

13. Amelia Nancy Black (3 out of 15 patents)

14. Antonio J Grillo-López (2 out of 3 patents)

15. Alan M Sonnenfeld (2 out of 2 patents)

Core Competencies:

Anti-CD20 Antibodies

Chimeric Antibodies

B-Cell Lymphomas

Autoimmune Diseases

Hematologic Malignancies

CD80-Specific Antibodies

Recombinant Antibodies

Gene Integration

Depth Filtration

Cancer Treatment

Immunosuppression

Cytotoxic T-Lymphocyte Responses

46 patents: Sort by Forward Citations

1. 9993550 - Treatment of pemphigus (2018-06-12),

2. 8821873 - Treatment of diffuse large-cell lymphoma with anti-CD20 antibody (2014-09-02),

3. 8608960 - Method of purifying polypeptides by simulated moving bed chromatography (2013-12-17),

4. 8557244 - Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody (2013-10-15),

5. 8545843 - Treatment of vasculitis (2013-10-01),

6. 8329172 - Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody (2012-12-11),

7. 8206711 - Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies (2012-06-26),

8. 7820161 - Treatment of autoimmune diseases (2010-10-26),

9. 7759117 - Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures (2010-07-20),

10. 7744877 - Expression and use of anti-CD20 Antibodies (2010-06-29),

11. 7682612 - Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody (2010-03-23),

12. 7604989 - Inhibition of apoptosis process and improvement of cell performance (2009-10-20),

13. 7510713 - Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies (2009-03-31),

14. 7510712 - Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies (2009-03-31),

15. 7501264 - Methods of producing 7C10 and 16C10 CD80-specific antibodies (2009-03-10),

Biogen is a global biotechnology company specializing in the development of therapies for neurodegenerative diseases, autoimmune disorders, and rare genetic conditions. With a focus on innovative research and cutting-edge technology, Biogen is committed to improving the lives of patients around the world. The company's portfolio includes leading treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and hemophilia. Biogen's dedication to scientific excellence and patient-centric care has established it as a leader in the biopharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

46 Patents

#1 in Weston, MA

#420 in Massachusetts

#7,326 in US

#14,671 in the World

Weston, MA, United States of America

Biogen Idec, Inc.

Forward Citations = 1,009

62 inventors:

Nabil Hanna (23 out of 40 patents)

Darrell R Anderson (14 out of 22 patents)

Peter Brams (12 out of 24 patents)

4. Mitchell E Reff (7 out of 25 patents)

5. Roland A Newman (7 out of 30 patents)

Please report any incorrect information to support@idiyas.com

Loading…